IPSC vs. ADVM, IPHA, KOD, CMPX, INMB, ABOS, ZURA, MGX, OPT, and AGEN
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Adverum Biotechnologies (ADVM), Innate Pharma (IPHA), Kodiak Sciences (KOD), Compass Therapeutics (CMPX), INmune Bio (INMB), Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Metagenomi (MGX), Opthea (OPT), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Century Therapeutics (NASDAQ:IPSC) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
Adverum Biotechnologies received 336 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 60.97% of users gave Adverum Biotechnologies an outperform vote while only 60.87% of users gave Century Therapeutics an outperform vote.
Century Therapeutics presently has a consensus price target of $13.20, indicating a potential upside of 338.54%. Adverum Biotechnologies has a consensus price target of $29.00, indicating a potential upside of 260.70%. Given Century Therapeutics' higher probable upside, equities analysts clearly believe Century Therapeutics is more favorable than Adverum Biotechnologies.
Adverum Biotechnologies has a net margin of 0.00% compared to Century Therapeutics' net margin of -9,742.41%. Century Therapeutics' return on equity of -59.74% beat Adverum Biotechnologies' return on equity.
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 7.6% of Century Therapeutics shares are held by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Adverum Biotechnologies has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
In the previous week, Century Therapeutics had 2 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 7 mentions for Century Therapeutics and 5 mentions for Adverum Biotechnologies. Century Therapeutics' average media sentiment score of 1.18 beat Adverum Biotechnologies' score of 0.22 indicating that Century Therapeutics is being referred to more favorably in the media.
Summary
Century Therapeutics beats Adverum Biotechnologies on 10 of the 17 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
